Recently, a phase 1/2 trial in advanced or metastatic solid tumors, including them non-small cell lung cancer, cervical, colorectal and BC, evaluates NGM707, a novel dual antagonist antibody that inhibits the ILT2 and ILT4, as a monotherapy or in combination with Pembrolizumab (ClinicalTrials.gov Identifier: NCT04913337). Here, LILRB1 is linked to breast cancer.